Literature DB >> 1619093

Biological markers, treatment outcome, and 1-year follow-up in endogenous depression: electroencephalographic sleep studies and response to cognitive therapy.

A D Simons1, M E Thase.   

Abstract

Although there are now considerable data attesting to the efficacy of several forms of treatment for depression, there is surprisingly little information to guide the selection of the treatment most likely to benefit a given patient. Biologic markers of depression have received much attention for their potential to provide theoretically and clinically meaningful subgroups for specific treatments. The relationship between electroencephalographic (EEG) sleep disturbances, treatment outcome, and 1-year follow-up was examined for a sample of 53 patients with endogenous major depression receiving cognitive-behavioral therapy. Overall, there was little support for the prediction of a difference in short- or long-term outcome between patients with and without EEG sleep disturbances.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1619093     DOI: 10.1037//0022-006x.60.3.392

Source DB:  PubMed          Journal:  J Consult Clin Psychol        ISSN: 0022-006X


  3 in total

1.  Stress sensitivity interacts with depression history to predict depressive symptoms among youth: prospective changes following first depression onset.

Authors:  Jessica R Technow; Nicholas A Hazel; John R Z Abela; Benjamin L Hankin
Journal:  J Abnorm Child Psychol       Date:  2015-04

2.  Insomnia and objectively measured sleep disturbances predict treatment outcome in depressed patients treated with psychotherapy or psychotherapy-pharmacotherapy combinations.

Authors:  Wendy M Troxel; David J Kupfer; Charles F Reynolds; Ellen Frank; Michael E Thase; Jean M Miewald; Daniel J Buysse
Journal:  J Clin Psychiatry       Date:  2011-11-29       Impact factor: 4.384

Review 3.  Prevalence and outcome of partial remission in depression.

Authors:  Richard Tranter; Claire O'Donovan; Praful Chandarana; Sidney Kennedy
Journal:  J Psychiatry Neurosci       Date:  2002-07       Impact factor: 6.186

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.